News stories about Sequenom (NASDAQ:SQNM) have trended somewhat positive on Friday, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sequenom earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.0432438554438 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Cell-Free DNA (cfDNA) Testing Market Research Report 2016-2024 (medgadget.com)
- Next-Generation Sequencing for Non-Invasive Prenatal Testing Market Technological breakthroughs By 2024 (openpr.com)
- Next-Generation Sequencing for Non-Invasive Prenatal Testing Market – Industry Size, Share, Analysis and Trading Growth to 2024 (medgadget.com)
- Avant Diagnostics Highlights Published Clinical Utility Data for - KAIT Jonesboro, AR - Region 8 News, weather, sports (kait8.com)
- Genotyping Global Market by Technology & Data Validation, Growth, Trends, Analysis and Forecast 2022 (emailwire.com)
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Sequenom (NASDAQ:SQNM) Stock Price” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://stocknewstimes.com/2017/07/21/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-sequenom-nasdaqsqnm-stock-price.html.
About Sequenom
Sequenom, Inc is a life sciences company. The Company serves patients and physicians by providing early patient management information. The Company operates through Sequenom Laboratories segment. It conducts its business as a molecular diagnostics clinical laboratory located in San Diego, California and Raleigh-Durham, North Carolina.
Receive News & Ratings for Sequenom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sequenom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
